Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-06-18 00:00:00 ET · period of report 2024-06-14 · accession 0002001011-24-000057 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-18 | 2024-06-14 | LGND | Haas Jason | Dir | A - Grant | $0.00 | +1,252 | 5,397 | +30% | $0 |
| D | 2024-06-18 | 2024-06-14 | LGND | Haas Jason | Dir | A - Grant | $0.00 | +5,444 | 5,444 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-14 | A | A | 1,252 | $0.00 | 5,397 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-06-14 | A | A | 5,444 | $0.00 | 5,444 | D | $80.06 · — to 2034-06-14 | 5,444 Common Stock | (F2) Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |